Revised Statement Of Investor Complaints For The Quarter Ended September 30, 2017
Update on Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2017 Novartis to present data from Cosentyx on potential to maintain mobility in patients with AS & PsA at 2017 ACR/ARHP meeting
New evidence on the efficacy of the innovative biologic Cosentyx (secukinumab) demonstrating its potential to reduce structural disease progression in patients with specific rheumatological conditions will be Novartis to shut US generics plant, cut 450 jobs
Second-quarter sales in the Sandoz division slipped 5%, which Novartis said was mainly due to pricing pressures in the US retail market. Compliance Certificate For The Period Ended September 30, 2017
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the Compliance Certificate, for half year ended September 30, 2017. Shareholding for the Period Ended September 30, 2017
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations 2015
Pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose herewith a Certificate from a Practicing Company Secretary confirming that all certificates have been issued within thirty days of the date of lodgement for transfer, sub-division, consolidation, renewal, etc. for the half year ended September 30, 2017. Statement Of Investor Complaints For The Quarter Ended September 30, 2017
Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please find enclosed statement of investor complaints/grievances for the quarter ended September 30, 2017. Statement Of Investor Complaints For The Quarter Ended September 30, 2017
Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please find enclosed statement of investor complaints/grievances for the quarter ended September 30, 2017. Board Meeting On November 10, 2017
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017; inter-alia to consider unaudited financial results of the Company for the second quarter and half year ended September 30, 2017. Further, a copy of this notice will be made available on the website of the Company www.novartis.in.